Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone909-980-9484
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$294.67 million
Profitability
Miscellaneous
Employees2,078
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) released its earnings results on Wednesday, August, 7th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.05. The firm had revenue of $79 million for the quarter, compared to analysts' expectations of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The company's quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.03 earnings per share. View Amphastar Pharmaceuticals' Earnings History.
When is Amphastar Pharmaceuticals' next earnings date?
What price target have analysts set for AMPH?
4 Wall Street analysts have issued 1 year price objectives for Amphastar Pharmaceuticals' stock. Their forecasts range from $22.20 to $29.00. On average, they anticipate Amphastar Pharmaceuticals' share price to reach $25.05 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.
What is the consensus analysts' recommendation for Amphastar Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amphastar Pharmaceuticals.
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
Headlines about AMPH stock have been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Amphastar Pharmaceuticals.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Allakos (ALLK), FibroGen (FGEN), Nektar Therapeutics (NKTR), Mirati Therapeutics (MRTX), Evotec (EVTCY), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR) and HUTCHISON CHINA/S (HCM).
What other stocks do shareholders of Amphastar Pharmaceuticals own?
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 69)
- Dr. Yongfeng Zhang, CEO, Chief Science Officer & Director (Age 72)
- Mr. Jason B. Shandell, Pres, Gen. Counsel & Director (Age 45)
- Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 51)
- Mr. Jacob Liawatidewi M.B.A., Sr. VP of Corp. Admin. Center, Sales and Marketing & Corp. Sec. (Age 45)
Who are Amphastar Pharmaceuticals' major shareholders?
Amphastar Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.55%), Vanguard Group Inc. (5.06%), Renaissance Technologies LLC (1.25%), Nuveen Asset Management LLC (1.22%), Northern Trust Corp (1.02%) and Bank of New York Mellon Corp (0.83%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, Stephen B Shohet, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.
Which institutional investors are selling Amphastar Pharmaceuticals stock?
AMPH stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Wells Fargo & Company MN, Argent Capital Management LLC, Bank of America Corp DE, Public Employees Retirement Association of Colorado, Skandinaviska Enskilda Banken AB publ and KBC Group NV. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.
Which institutional investors are buying Amphastar Pharmaceuticals stock?
AMPH stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Point72 Asset Management L.P., Renaissance Technologies LLC, First Trust Advisors LP, BlackRock Inc., Vanguard Group Inc., DekaBank Deutsche Girozentrale and Pinebridge Investments L.P.. View Insider Buying and Selling for Amphastar Pharmaceuticals.
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $20.97.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $990.33 million and generates $294.67 million in revenue each year. The company earns $-5,740,000.00 in net income (profit) each year or $0.21 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,078 workers across the globe.View Additional Information About Amphastar Pharmaceuticals.
What is Amphastar Pharmaceuticals' official website?
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (NASDAQ AMPH)
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
